Results indicated POLE mutations as a favorable biomarker for improved OS in squamous cell carcinoma patients (p = 0.033) only, although POLE mutated adenocarcinomas with high expression of PD-L1 also exhibited improved OS (p = 0.024). Here, POLE is linked to adenocarcinoma.